UCB submits New Drug Application for Xyzal

By Elaine Rigoli

Tampa, Fla., July 27 - UCB, Inc. submitted a New Drug Application to the Food and Drug Administration for the approval of Xyzal (levocetirizine dihydrochloride), a new prescription antihistamine for treatment of allergy symptoms.

UCB said it requested the following indications: seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria.

"The NDA submission for Xyzal is an alternative for U.S. physicians seeking an effective prescription treatment for patients that do not experience relief with existing medicines. UCB is committed to helping meet unmet medical needs for patients with allergy symptoms that negatively impact their quality of life," chief executive officer Roch Doliveux said in a news release.

UCB is a biopharmaceutical company with worldwide headquarters in Brussels, Belgium, and U.S. headquarters in Atlanta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.